Table 1.
Baseline characteristics and pre-existing comorbidities of study cohorts.
| First dose |
Second dose |
|||||||
|---|---|---|---|---|---|---|---|---|
| None |
BNT162b2 |
CoronaVac |
SMD |
None |
BNT162b2 |
CoronaVac |
SMD |
|
| N | 2816133 | 579998 | 542795 | – | 1892783 | 388881 | 332707 | – |
| Male (%) | 1183236 (42.0) | 275965 (47.6) | 266681 (49.1) | 0.095 | 831868 (43.9) | 190562 (49.0) | 175487 (52.7) | 0.118 |
| Age (mean (SD)) | 55.67 (19.17) | 46.72 (15.06) | 54.01 (13.85) | 0.374 | 56.81 (19.27) | 47.49 (14.88) | 54.67 (13.97) | 0.389 |
| Charlson Comorbidity Index (mean (SD)) | 0.35 (0.91) | 0.10 (0.41) | 0.15 (0.49) | 0.250 | 0.37 (0.93) | 0.10 (0.41) | 0.15 (0.49) | 0.263 |
| Myocardial infarction (%) | 16935 (0.6) | 617 (0.1) | 891 (0.2) | 0.057 | 12229 (0.6) | 418 (0.1) | 548 (0.2) | 0.060 |
| Congestive Heart Failure (%) | 32695 (1.2) | 425 (0.1) | 912 (0.2) | 0.096 | 24414 (1.3) | 302 (0.1) | 581 (0.2) | 0.102 |
| Peripheral vascular disease (%) | 7525 (0.3) | 249 (0.0) | 362 (0.1) | 0.039 | 5631 (0.3) | 175 (0.0) | 240 (0.1) | 0.042 |
| Cerebrovascular disease (%) | 111165 (3.9) | 4309 (0.7) | 7350 (1.4) | 0.145 | 80569 (4.3) | 2964 (0.8) | 4611 (1.4) | 0.153 |
| Stroke or systemic embolism (%) | 37828 (1.3) | 1226 (0.2) | 2197 (0.4) | 0.088 | 27494 (1.5) | 852 (0.2) | 1360 (0.4) | 0.093 |
| Asthma (%) | 27317 (1.0) | 3665 (0.6) | 3309 (0.6) | 0.027 | 18798 (1.0) | 2468 (0.6) | 2043 (0.6) | 0.028 |
| Chronic obstructive pulmonary disease (%) | 58132 (2.1) | 4778 (0.8) | 5343 (1.0) | 0.070 | 41664 (2.2) | 3244 (0.8) | 3365 (1.0) | 0.075 |
| Dementia (%) | 11122 (0.4) | 103 (0.0) | 149 (0.0) | 0.057 | 8477 (0.4) | 69 (0.0) | 105 (0.0) | 0.061 |
| Diabetes without chronic complication (%) | 351241 (12.5) | 27787 (4.8) | 41633 (7.7) | 0.185 | 245849 (13.0) | 18561 (4.8) | 25251 (7.6) | 0.196 |
| Diabetes with chronic complication (%) | 20940 (0.7) | 871 (0.2) | 1302 (0.2) | 0.060 | 14766 (0.8) | 594 (0.2) | 795 (0.2) | 0.063 |
| Chronic renal failure (%) | 38702 (1.4) | 1155 (0.2) | 2048 (0.4) | 0.091 | 28288 (1.5) | 778 (0.2) | 1297 (0.4) | 0.097 |
| Mild liver disease (%) | 4056 (0.1) | 231 (0.0) | 324 (0.1) | 0.023 | 2846 (0.2) | 158 (0.0) | 188 (0.1) | 0.024 |
| Moderate-severe liver disease (%) | 2871 (0.1) | 141 (0.0) | 188 (0.0) | 0.021 | 1980 (0.1) | 95 (0.0) | 108 (0.0) | 0.021 |
| Rheumatoid arthritis and other inflammatory polyarthropathies (%) | 10584 (0.4) | 813 (0.1) | 873 (0.2) | 0.031 | 7010 (0.4) | 479 (0.1) | 456 (0.1) | 0.033 |
| Malignancy (%) | 75657 (2.7) | 4682 (0.8) | 5220 (1.0) | 0.096 | 52132 (2.8) | 3054 (0.8) | 3107 (0.9) | 0.100 |
| Metastatic solid tumor (%) | 14757 (0.5) | 348 (0.1) | 418 (0.1) | 0.058 | 10256 (0.5) | 226 (0.1) | 234 (0.1) | 0.060 |
Note: P-values for vaccinated and non-vaccinated groups comparison all <0.001. Abbreviation: SMD, standard mean difference (defined as the average of SMD among unvaccinated, CoronaVac and BNT162b2).